Roche pulls out of deal with Inovio on hepatitis B vaccine

4 August 2016

Swiss pharma giant Roche (ROG: SIX) has notified Inovio Pharmaceutical (Nasdaq: INO) that it will discontinue its collaboration with Inovio and its development of INO-1800.

Inovio responded by saying it will continue to develop its hepatitis B DNA immunotherapy (INO-1800) vaccine independently. The company’s shares dipped as low as $9.66 by around 10 am, before recovering to $9.84, a rise of 2.45% by 11 am on Wednesday’s closing price.

All of Roche's rights to INO-1800, including the right to license the product to other parties, will be returned. Inovio will continue to advance its current Phase I study of INO-1800, which is enrolling as planned in 30 clinical sites in USA and Asia-Pacific regions. Inovio anticipates completing enrollment in the first half of 2017 and expects results in the second half of 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK